Articles tagged "Tumor recurrence"

2022 American Transplant Congress
Degree of Pre-Liver Transplant Immune Dysfunction Correlates with Post-Transplant Cancer Recurrence
G. S. Prakash¹, G. G. Panayotova¹, S. Simonishvili¹, Y. Qin¹, L. Jin¹, T. Ayorinde¹, L. J. Minze², F. Paterno¹, L. Brown¹, A. Amin¹, D. Liu¹, R. Ghobrial², J. V. Guarrera¹, K. E. Lunsford¹
¹Rutgers New Jersey Medical School, Newark, NJ, ²Houston Methodist Hospital, Houston, TX
*Purpose: Despite stringent selection criteria for liver transplant (LT) in patients with liver-limited malignancy, post-transplant cancer recurrence remains problematic. We have previously identified a pre-LT…
2022 American Transplant Congress
Clinical Efficacy of Adjuvant Immunotherapy for Liver Transplant Recipients with Exceeding Japan Criteria of Hepatocellular Carcinoma Using Donor Liver Derived Natural Killer Cells
M. Ohira¹, Y. Imaoka², K. Sato³, K. Imaoka¹, N. Tanimine¹, H. Tahara¹, K. Ide¹, T. Kobayashi¹, Y. Tanaka¹, A. G. Tzakis⁴, S. Nishida⁵, H. Ohdan¹
¹Hiroshima University, Hiroshima, Japan, ²Hiroshima Uni., Hiroshima, Japan, ³Department of Gastroenterological and Transplant Surgery, Hiroshima University, Hiroshima, Japan, ⁴Digestive Diseases and Surgery Institute, Cleveland Clinic, Cleveland, OH, ⁵Univ of Miami School of Medicine, Valhalla, NY
*Purpose: Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide and is an indication for liver transplantation (LT). Immunosuppressive regimens currently used after…
2022 American Transplant Congress
Induction Immunosuppression Does Not Worsen Tumor Recurrence After Liver Transplantation for T2 Hepatocellular Carcinoma and May Allow for Decreased Mortality
C. Durkin¹, T. Bittermann¹, D. E. Schaubel²
¹Gastroenterology, University of Pennsylvania, Philadelphia, PA, ²Biostatistics, University of Pennsylvania, Philadelphia, PA
*Purpose: Prior studies have suggested that induction therapy leads to worse outcomes after liver transplantation (LT) for hepatocellular carcinoma (HCC). This study evaluated the impact…
2022 American Transplant Congress
Mortality in Solid Organ Transplant Recipients with a Pretransplant Cancer Diagnosis
A. Hart¹, R. Pfeiffer², B. Morawski³, C. Lynch⁴, Y. Zeng⁵, K. Pawlish⁶, K. Yu⁷, D. Hurley⁸, E. Engels⁷
¹Hennepin Healthcare, University of Minnesota, Minneapolis, MN, ²Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, ³Cancer Registry of Idaho, Boise, ID, ⁴Epidemiology, University of Iowa, Iowa City, IA, ⁵North Dakota Statewide Cancer Registry, Grand Forks, ND, ⁶New Jersey State Cancer Registry, Trenton, NJ, ⁷Infections and Immunoepidemiology Branch, National Cancer Institute, Bethesda, MD, ⁸University of South Carolina, Columbia, SC
*Purpose: Transplant-associated immunosuppression may cause cancer recurrence in patients with a pretransplant cancer, but little is known about outcomes among these recipients.*Methods: We used data…
2022 American Transplant Congress
Prevalence and Clinical Significance of Pancreatic Cystic Lesions in Immunosuppressed Patients with Solid Organ Transplantation
Y. Yu, H. Jo, Y. Choi, J. Lee, D. Kim
HBP surgery and liver transplantation, Korea University College of Medicine and School of Medicine, Seoul, Korea, Republic of
*Purpose: Solid organ transplant recipients have an increased risk of cancer due to immunosuppressive therapy. Pancreatic cystic lesions (PCLs) are increasingly being detected, some with…
2022 American Transplant Congress
Everolimus in Liver Transplantation for Diffuse, Unresectable Neuroendocrine Tumor
J. M. Vanatta¹, R. A. Helmick², C. Eymard², N. Nezakatgoo², P. Horton², J. P. Kothadia², S. P. Nair², J. D. Eason²
¹Transplantation, University of Tennessee/Methodist University Hospital, Memphis, TN, ²Transplantation, University of Tennessee, Memphis, TN
*Purpose: Liver transplantation (LT) has emerged as a therapy in selected patients for neuroendocrine tumor (NET) by providing cytoreduction. Progression-free survival in NET has been…
2022 American Transplant Congress
Atherosclerosis Reduces Anti-Tumor Activity of Liver-Resident Natural Killer Cells
K. Imaoka, M. Ohira, K. Sato, Y. Imaoka, R. Nakano, H. Ohdan
Department of Gastroenterological and Transplant Surgery, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan
*Purpose: Abdominal aorta calcification (AAC) is associated with an increased relative risk of coronary events, cerebrovascular events, cardiovascular events, and cardiovascular death. We report that…
2021 American Transplant Congress
Pilot Evaluation of Prognosis After Liver Transplantation in Patients with a History of Hepatocellular Carcinoma and Pd-1 Inhibition
M. Chen¹, Z. Chen¹, X. Lin²
¹First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China, ²the Eastern Hospital of the First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
*Purpose: The successful applications of programmed death protein-1 (PD-1) inhibitors in cancer therapy has led to an expanding use of immunotherapy in oncolog Liver transplantation…
2021 American Transplant Congress
Adjuvant Immunotherapy for Liver Transplant Recipients with Hepatocellular Carcinoma Using Donor Liver-derived Natural Killer Cells
M. Ohira¹, R. Hotta¹, Y. Imaoka¹, K. Sato¹, N. Tanimine¹, Y. Tanaka¹, S. Nishida², A. Tzakis², H. Ohdan¹
¹Hiroshima University, Hiroshima, Japan, ²University of Miami, Miami, FL
*Purpose: Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide and is an indication for liver transplantation (LT). Immunosuppressive regimens currently used after…
2021 American Transplant Congress
Living Donor Liver Transplant for Unresectable Colorectal Metastasis: A Case Series
B. Emmanuel, H. Al-Harakeh, A. Humar, C. Hughes, A. Tevar, M. Molinari, A. Ganoza
Starzl Transplant Institute, UPMC, Pittsburgh, PA
*Purpose: Colorectal Cancer (CRC) represents the third most common malignancy worldwide. In the US, CRC lifetime risk is approximately 1 in 23 (4.4%) for men…

1
2
3
…
5
Next Page »